Abstract Library

#2867 Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia

Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Markovich A, Kuznetsova A, Gorbunova V, Orel N, Emelianova G,

Keywords: neuroendocrine tumors, everolimus, uni- and multivariate analysis,

#2298 Large Cell Neuroendocrine Carcinoma of the Lung with Atypical Evolution and Great Response to Innovative Treatments

Introduction: Pulmonary neuroendocrine tumors are a group of heterogeneous neoplasms that represent 1% to 2% of all lung cancers.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Escala Cornejo R

Authors: Escala Cornejo R, Navarro M, García-Talavera SanMiguel P, Pérez López B, García Muñoz M,

Keywords: LCNEC,

#2082 Evaluation of Everolimus (EVE) in Patients with Metastatic Lung Neuroendocrine Tumors

Introduction: Lung neuroendocrine tumors are rare, but their incidence has been steadily increasing in recent years.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Kuznetsova A, Gorbunova V, Orel N, Emelianova G, Markovich A,

Keywords: lung neuroendocrine tumors, Everolimus,

#1778 Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinomas: Does the Regimen Matter?

Introduction: Metastatic pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare disease and the most effective chemotherapy regimen is debated, i.e. small cell lung carcinoma (SCLC) or non-small cell lung carcinoma (NSCLC) chemotherapy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Derks J

Authors: Derks J, Suylen R, Thunnissen E, Den Bakker M, Groen H,

Keywords: lcnec, chemotherapy, nec, lung,

#1702 Comparative Retrospective Analysis of pNETs Treatment with Everolimus (E) and Sunitinib (S).

Introduction: Two targeted compounds are validated for treatment of pNETs – E and S.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Kouzminov A, Odintsova A, Polozkova S, Orel N, Markovich A,

Keywords: pNETs, sunitinib, everolimus,